The Chinese Herbal Medicine *Sophora Flavescens* Activates Pregnan X Receptor

Laiyou Wang¹, Feng Li, Jie Lu, Guodong Li, Dan Li, Xiao-bo Zhong, Grace L. Guo, and Xiaochao Ma

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160
Running title: *Sophora Flavescens Activates Pregnane X Receptor*

Corresponding author: Xiaochao Ma, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160; Phone: (913) 588-1749; Fax: (913) 588-7501; Email: xma2@kumc.edu

Number of text pages: 24
Number of tables: 0
Number of figures: 6
Number of references: 40
Words in abstract: 209
Words in introduction: 540
Words in discussion: 800

Abbreviations:

SF, *Sophora flavescens*; SCB, *Schisandraceae Chinensis Baili*; GUF, *Glycyrrhiza Uralensis Fisch*; P450, cytochrome P450; CYP3A, cytochrome P450 3A; PXR, pregnane X receptor; CAR, constitutive androstane receptor; DMSO, dimethyl sulfoxide; qPCR, quantitative real-time PCR; TOFMS, time of flight mass spectrometry; UPLC, ultra performance liquid chromatography; PCA, principal components analysis; OPLS-DA, orthogonal projection to latent structures-discriminant analysis.
Abstract

*Sophora flavescens* (SF) is an herbal medicine widely used for the treatment of viral hepatitis, cancer, viral myocarditis, gastrointestinal hemorrhage and skin diseases. It was recently reported that SF upregulates cytochrome P450 3A (CYP3A) expression. The mechanism of SF-induced CYP3A expression is unknown. In the current study, we tested the hypothesis that SF-induced CYP3A expression is mediated by the activation of pregnane X receptor (PXR). We used two cell lines, DPX2 and HepaRG, to investigate the role of PXR in SF-induced CYP3A expression. The DPX2 cell line is derived from HepG2 cells with the stable transfection of human *PXR* and a luciferase reporter gene linked with a human PXR response element identified in the *CYP3A4* gene promoter. In DPX2 cells, SF activated PXR in a concentration-dependent manner. We used a metabolomic approach to identify the chemical constituents in SF, which were further analyzed for their effect on PXR activation and CYP3A regulation. One chemical in SF, *N*-methylcytisine, was identified as an individual chemical that activated PXR. HepaRG is a highly differentiated hepatoma cell line that mimics human hepatocytes. In HepaRG cells, *N*-methylcytisine significantly induced CYP3A4 expression, and this induction was suppressed by the PXR antagonist sulforaphane. These results suggest that SF induces CYP3A expression via the activation of PXR.
Introduction

*Sophora flavescens* (SF) is widely used in traditional Chinese medicine for the treatment of viral hepatitis, cancer, viral myocarditis, gastrointestinal hemorrhage and skin diseases (Dai et al., 1987; Chen et al., 2000; Sun et al., 2007; Jin et al., 2010). In recent decades, the market for SF has expanded worldwide (Dharmananda, 1998). The potential SF-drug interactions are unknown. To assess SF-drug interactions, Ueng *et al.* investigated the effect of SF on the expression of hepatic cytochromes P450 (P450) in mice. Among the tested P450s, Cyp1a, 2a, 2b, and 3a were induced by SF (Ueng et al., 2009). Matrine and oxymatrine are two major pharmacologically active constituents in SF (Ling et al., 2007). Both matrine and oxymatrine have been found to induce CYP2B, but not CYP3A (Yuan et al., 2010). Cell-based reporter gene assay indicated that CYP2B induction by matrine and oxymatrine is mediated by a constitutive androstane receptor (CAR) (Yuan et al., 2010). CAR is a member of the nuclear receptor superfamily regulating the transcription of target genes involved in drug metabolism, such as *CYP2B* and *CYP3A* (Baes et al., 1994; Maglich et al., 2002). However, matrine and oxymatrine exhibited no significant effect on the regulation of *CYP3A*, which might be because (i) matrine and oxymatrine are weak CAR activators, as CAR can only be activated by the high concentration of matrine and oxymatrine (~300 µM) (Yuan et al., 2010); (ii) CAR exhibits a significantly higher selectivity for CYP2B induction than for CYP3A induction (Faucette et al., 2006); and (iii) the basal level of CYP2B is much lower than CYP3A, so the induction of CYP2B reaches a statistically significant level more readily than that of CYP3A. The mechanism of SF-mediated CYP3A induction remains unclear.
Pregnane X receptor (PXR) is a ligand-activated transcriptional factor regulating drug metabolism. When activated, PXR induces a network of genes that encode phase I (including CYP3A) and phase II xenobiotic metabolizing enzymes and transporters (Kliewer et al., 1998; Ma et al., 2008). Compared with CAR, PXR is a more important regulator of CYP3A (Kliewer et al., 1998; Goodwin et al., 2002; Faucette et al., 2006). We hypothesized that SF-induced CYP3A expression is mediated by the activation of PXR. Two cell lines, DPX2 and HepaRG, were used to investigate the role of PXR in SF-induced CYP3A expression. The DPX2 cell line is derived from HepG2 cells with the stable transfection of human PXR and a luciferase reporter gene linked with a human PXR response element identified in the CYP3A4 gene promoter (Raucy et al., 2002; Trubetskoy et al., 2005). The DPX2 cell line has been identified as an ideal tool to evaluate the PXR activators and CYP3A4 inducers. HepaRG is a highly differentiated cell line that mimics human hepatocytes with the expressions of multiple nuclear receptors and P450s, including PXR and CYP3A4 (Antherieu et al., 2010). HepaRG is regarded as a valuable model to investigate the induction of drug-metabolizing P450s (Kanebratt and Andersson, 2008). We used a metabolomic approach to identify the chemical constituents in SF, and further analyzed these relatively abundant chemicals for their effect on PXR activation and CYP3A regulation. We demonstrated that SF-induced CYP3A expression was mediated by the activation of PXR. One constituent in SF, N-methylcytisine, was identified as a novel PXR activator.
Materials and Methods

Herbs, Chemicals, and Reagents

SF, *Schisandraceae Chinensis Baili* (SCB) and *Glycyrrhizae Uralensis Fisch* (GUF) were obtained from the Guangdong Kangmei Pharmaceutical Company (Puning, Canton, China). SCB and GUF served as positive controls of herbs that activate PXR (Mu et al., 2006). Chemical constituents of SF, sophocarpine, allomatrine, N-methylcytisine and sophoranol, were purchased from Quality Phytochemicals LLC (Edison, NJ); oxymatrine, matrine and tetrandrine were bought from INDOFINE Chemical Company (Hillsborough, NJ). The culturing medium and dosing medium for DPX2 cells were purchased from Puracyp Inc. (Carlsbad, CA). William’s medium E with phenol red and fetal bovine serum for HepaRG cells was bought from Invitrogen (Carlsbad, CA). The luciferase assay system was provided by Promega Inc. (Madison, WI). TRIzol® reagent was provided by Ambion (Austin, TX). Taqman® Universal PCR Master Mix was acquired from Applied Biosystems (Carlsbad, CA). Midazolam was purchased from Cerilliant (Round Rock, TX). All the solvents for liquid chromatography and mass spectrometry were of the highest grade commercially available.

Preparations of Herbal Extracts

Six grams of dried roots of SF, SCB and GUF were individually immersed into 300 ml of H₂O for 30 min and boiled for 1 h. Each aqueous extract was filtered and centrifuged at 10,000 rcf. The supernatant was concentrated using a rotary evaporator to a final volume of 60 ml and served as stock solution. Twenty mM stock solution of each SF constituent was made in dimethyl sulfoxide (DMSO). The stock solutions were diluted to different concentrations in the cell culture medium before the treatments.
Cell Cultures and Treatments

Two cell lines, DPX2 and HepaRG, were used to determine the role of PXR in SF-induced CYP3A expression. The DPX2 cell line is derived from HepG2 cells with the stable transfection of human PXR and a luciferase reporter gene (Raucy et al., 2002; Trubetskoy et al., 2005). The DPX2 cell line was used for a large scale screening of PXR activators. HepaRG cells mimic human hepatocytes with the expressions of multiple nuclear receptors and P450s, including PXR and CYP3A4 (Antherieu et al., 2010). HepaRG cells were used for the functional analysis of PXR activation. The DPX2 cell line at passage 10 (Lot number 4542) was provided by Puracyp, Inc. DPX2 cells were treated following standard operating procedures (SOP# 105.04 and 116.03, Puracyp, Inc.). Briefly, cells were cultured in a 96-well plate with a density of $2 \times 10^5$ cells/ml (100 µl each well) in culturing medium. After 24 h incubation, the culturing medium was removed and 150 µl of the dosing medium with test compound(s) was added. HepaRG cells were provided by Biopredic International (Rennes, France). The undifferentiated HepaRG cells were seeded at 0.2 million cells/well in a 6-well plate, maintained in the growth medium (Biopredic International) for two weeks, and then cultured in the differentiation medium containing 2% DMSO for two more weeks. HepaRG cells mimic human hepatocytes and express multiple xenobiotic receptors, including PXR, CAR, and aryl hydrocarbon receptor (Guillouzo et al., 2007). A highly selective PXR antagonist, sulforaphane (Zhou et al., 2007), was used in the treatment of HepaRG cells to specify the role of PXR. The SF aqueous extract and its major chemical constituents were incubated in both DPX2 and HepaRG cell lines, followed by analysis of luciferase activity and CYP3A4 expression and activity. The method for the luciferase assay was described in a previous study (Ma et al., 2007b). All experiments were performed in triplicate.
Cell Viability

The viability of DPX2 and HepaRG cells was evaluated using the ATP Detection Assay System (PerkinElmer Inc., Waltham, MA) and CytoToX-ONE™ Homogeneous Membrane Integrity assay for LDH (Promega Inc., Madison, WI). Among the tested concentrations of SF and its constituents, no significant cytotoxicity was noted (data not shown).

Analysis of CYP3A4 Expression and Activity

After 48 h treatment with SF and its constituents in DPX2 and HepaRG cells, the total RNA was extracted using the Trizol reagent. cDNA was prepared from 1 µg of total RNA. CYP3A4 mRNA was quantified using quantitative real-time PCR (qPCR) (Cheng et al., 2009). Values were quantified using the comparative CT method, and samples were normalized to GAPDH. For CYP3A activity analysis, the culture medium containing SF aqueous extract and its constituents was withdrawn after 48 h treatment, and replaced by the medium containing 50 µM midazolam. Midazolam was used as a probe for CYP3A activity analysis (Ma et al., 2007a). After 2 h incubation, 100 µl of the medium was taken out. An equal volume of cold acetonitrile was added and centrifuged at 10,000 rcf. The top layer of the mixture was injected into an ultraperformance liquid chromatography (UPLC) with time-of-flight mass spectrometry (TOFMS) for midazolam metabolite analysis.

UPLC-TOFMS Analysis

UPLC-TOFMS was used to analyze SF constituents and to detect midazolam metabolite. Briefly, a 100 mm × 2.1 mm (Acquity 1.7 µm) UPLC BEH C-18 column (Waters, Milford, MA)
was used for chemical separation. The flow rate of the mobile phase was 0.3 ml/min with a
gradient ranging from 2% to 98% aqueous acetonitrile containing 0.1% formic acid in a 10 min
run. TOFMS was operated in positive mode with electrospray ionization. The source
temperature and desolvation temperature were set at 120°C and 350°C, respectively. N2 was
applied as the cone gas (10 L/h) and desolvation gas (700 L/h). Argon was applied as the
collision gas. TOFMS was calibrated with sodium formate and monitored by the intermittent
injection of lock mass leucine enkephalin in real time. The capillary voltage and the cone
voltage were set at 3.5 kV and 35 V in a positive ion mode. The structure of each chemical was
elucidated by tandem mass spectrometry fragmentation with collision energy ramp ranging from
10 to 30 eV.

Data Analysis

All values are expressed as mean ± S.D., and data were analyzed by two-tailed Student’s t test. p
< 0.05 was regarded as significantly different between groups. For the metabolomic analysis of
SF constituents, mass chromatograms and mass spectra were acquired by MassLynx software
(Waters, Milford, MA) in a centroid format from m/z 50 to 1000. Centroid and integrated mass
chromatographic data were processed by MarkerLynx software (Waters, Milford, MA) to
generate a multivariate data matrix. The corresponding data matrices were then exported into
SIMCA-P+12 (Umetrics, Kinnelon, NJ) for multivariate data analysis. Principal component
analysis (PCA) and orthogonal projection to latent structures-discriminant analysis (OPLS-DA)
were conducted on Pareto-scaled data to analyze the chemical constituents of SF.
Results

PXR Activation by SF

The effects of SF, SCB and GUF extracts on PXR were evaluated in DPX2 cells. SCB and GUF aqueous extracts served as positive controls for herb-mediated PXR activation (Mu et al., 2006). Similar to SCB and GUF, SF strongly activated PXR, as the luminescence increased 11-fold when compared with the vehicle control (Figure 1A). In addition, a dose-dependent PXR activation by SF was noted (Figure 1B).

The Chemical Constituents of SF

SF aqueous extract is expected to contain chemical(s) that activate PXR. The chemical constituents of SF aqueous extract were profiled using a LC-MS-based metabolomic approach. The results of chemometric analysis on the ions produced by UPLC-TOFMS are shown in Figure 2. The score plot of unsupervised PCA analysis (Figure 2A) revealed two clusters corresponding to the control and SF aqueous extract. The corresponding S-plot (Figure 2B) generated from OPLS-DA displayed the ion contribution to the group separation of control and SF aqueous extract. Top ranking ions in SF aqueous extract were marked in the S-plots (Figure 2B), which were identified as oxymatrine (I), oxysophocarpine (II), matrine (III), sophocarpine (IV) and N-methylcytisine (V). The structures of these chemicals were confirmed by comparing their retention times and mass fragments with those of commercially available standards. The confirmation of N-methylcytisine (C₁₂H₁₆N₂O) in SF extract is shown in Figure 3. The N-methylcytisine had exactly the same retention time (0.97 min) and mass fragments (58, 108, 146, and 162) as the authentic standard. Individual chemicals were further evaluated for their effect on PXR activation and CYP3A expression.
Screening PXR Activator(s) from SF Constituents

The top ranking ions in the metabolomic analysis of SF aqueous extract were screened for their effects on PXR. *N*-methylcytisine significantly activated PXR, as the luciferase activity increased ~10-fold in DPX2 cells (Figure 4A). The other tested SF constituents, such as oxymatrine, matrine, sophocarpine, and allomatrine, had no significant effect on PXR. As shown in Figure 4B, *N*-methylcytisine activated PXR in a concentration-dependent manner in DPX2 cells with a median effective concentration at ~8.9 µM.

*SF and N*-methylcytisine–mediated CYP3A4 Induction

After the treatment with different concentrations of SF aqueous extract and *N*-methylcytisine in DPX2 and HepaRG cells, CYP3A4 mRNA expression was quantified by qPCR. SF aqueous extract induced CYP3A4 mRNA expression in a concentration-dependent manner in DPX2 cells (Figure 5A). Significant induction of CYP3A4 by *N*-methylcytisine was also noted in DPX2 cells (Figure 5A). Similar to the results in DPX2 cells, both SF aqueous extract and *N*-methylcytisine upregulated CYP3A4 mRNA expression in HepaRG cells (Figure 5B). Sulforaphane, a PXR antagonist (Zhou et al., 2007), significantly abolished *N*-methylcytisine-mediated CYP3A4 upregulation in HepaRG cells (Figure 5C), suggesting that CYP3A4 induction by *N*-methylcytisine is PXR-dependent. Consistent with the CYP3A4 expression level, CYP3A activity was significantly increased in DPX2 cells after the pre-treatment of SF aqueous extract and *N*-methylcytisine (Figure 6). Pretreatment with oxymatrine, matrine, sophocarpine, and allomatrine had no significant effect on CYP3A activity (Figure 6).
Discussion

Herbal medicines or supplements are used worldwide (Kraft, 2009). The safety and efficacy of herb-drug combinations are largely unknown. Research on herb-drug interactions is urgently needed to guide herbal usage (Chan et al., 2010). Metabolism-mediated herb-drug interactions are very common, which might decrease the efficacy and/or increase the toxicity of the combined drug. The nuclear receptor PXR is a xenobiotic sensor, which regulates a large number of enzymes and transporters that contribute to drug metabolism and disposition (Kliewer et al., 1998; Ma et al., 2008). St. John’s wort is an herb that has drawn a lot of attention because of herb-drug interactions. PXR was identified as the key mediator in St. John’s wort-drug interactions (Moore et al., 2000; Mannel, 2004). In recent years, PXR has been considered as a molecular target to predict herb-drug interactions. SCB, GUF, ginkgo biloba, tian xian, and coleus forskohlii were reported as herbs that activate PXR (Ding and Staudinger, 2005; Mu et al., 2006; Lichti-Kaiser and Staudinger, 2008; Li et al., 2009). In the current study, we identified that SF activates PXR.

PXR is the dominant activator of CYP3A transcription (Kliewer et al., 1998; Goodwin et al., 2002; Kliewer et al., 2002). Activation of human PXR results in the transcriptional activation of CYP3A involving the formation of a heterodimer with retinoid X receptor, which binds to PXR response elements in the 5′-flanking region of the CYP3A4 gene (Goodwin et al., 1999). By identifying that SF activates PXR, we uncovered the mechanism of SF-mediated CYP3A induction. CYP3A is an important metabolic enzyme that is responsible for metabolizing over 50% of current prescription drugs (Guengerich, 1999). The most common clinical implication for the activation of the human PXR is the occurrence of drug-drug interactions mediated by
upregulated CYP3A isozymes. However, there is no clinical report on the SF-drug interactions, although SF can induce CYP3A and some other P450s (Ueng et al., 2009). It might be because no clinical trials were done on the SF-drug interactions. On the other hand, it might be due to the inhibitory effect of SF on P450s. During the screening of herbal medicines that inhibit CYP3A activity, SF showed the highest potency, which suggested there are CYP3A inhibitors in SF constituents (Lee et al., 2007). When CYP3A inducers and inhibitors are co-treated with drugs as CYP3A substrates, the effect of CYP3A inducers in drug-drug interactions is not significant, because the CYP3A inhibitors mask the effect of CYP3A inducers (Hafner et al., 2010). However, when the inhibitor is withdrawn, the effect of CYP3A inducers will be present because of the high expression of CYP3A. In the current study, we cultured the cells with the medium containing SF aqueous extract or its constituents for 48 h, and then the culture medium was withdrawn before CYP3A activity analysis. As expected, a significant increase of CYP3A activity was observed, which suggested that SF-drug interactions might occur in an early period after SF withdrawal.

Studies on herb-drug interaction are always challenging because an herb is a chemical mixture, and its constituents vary when the herb is collected from different locations and seasons, as well as extracted by different methods. Profiling the chemicals in an herb is a critical step to understand the potential herb-drug interactions. In the current study, we adopted the metabolomic approach to profile the chemical constituents in SF. Metabolomics is the systematic study of small molecule metabolite profiles that are left behind as unique chemical fingerprints by biologic processes. The metabolomic approach has been practiced and identified as a powerful tool to disclose the dark cassette of the traditional herbs (Rochfort, 2005; Xie et al.,
2008). By combining the speed and resolving power of UPLC, the accurate mass determination of TOFMS, and multivariate data analysis such as PCA and OPLS-DA, we can collect the overall chemical information in an herb, which can subsequently be used to guide research on herbal medicine. This method has a big advantage in the large scale analysis of herbs and thus accelerates the research on herbs. In the current study, we profiled the chemical constituents of SF and the top ranking chemicals were analyzed for their effect on PXR. \( N \)-methylcytisine was identified as a novel PXR activator. \( N \)-methylcytisine has also been isolated from other herbs, such as sophora secundiflora and caulophyllum thalictroides (Izaddoost et al., 1976; Ding et al., 2006). We expect that these herbs can also activate PXR at different levels based on their abundance of \( N \)-methylcytisine. These data indicated that the metabolomic approach is an ideal tool to profile the chemical constituents in an herb, and it has great implications in pharmacological and toxicological research on herbs.

In summary, SF-induced CYP3A expression is mediated by the activation of PXR. \( N \)-methylcytisine is a chemical in SF that activates PXR. The potential SF-drug interactions should be monitored in clinical practice.
Acknowledgements

We thank Puracyp, Inc. for providing DPX2 cells and Biopredic International for providing HepaRG cells. We thank Dr. Martha Montello for editing the manuscript.
References


X receptor and increase warfarin clearance in rats. *J Pharmacol Exp Ther* **316**:1369-1377.


Footnotes

This work was supported by the National Institutes of Health National Center for Research Resources [COBRE 5P20-RR021940].Current address (L.W.): Department of Pharmacology, Guangdong Pharmaceutical University, 280 Waihuan East Road, Guangzhou, 510006, China
Figure legends

Figure 1. A cell-based PXR gene reporter assay of SF aqueous extract. DPX2 cells were incubated with SF aqueous extract for 24 h. Results are shown as the fold induction of luciferase activity over the vehicle control. (A) The effect of SF aqueous extract (480 mg/L) on PXR activation in DPX2 cells. SCB and GUF aqueous extracts (480 mg/L) served as positive controls for herb-mediated PXR activation. The data are presented as mean ± SD (n=3), *p<0.05 vs control. (B) Concentration-dependent PXR activation in DPX2 cells by SF aqueous extract. The data are presented as mean (n=3 at each concentration).

Figure 2. Global profiling of the chemical constituents of SF aqueous extract using an LC-MS-based metabolomic approach. UPLC-TOFMS was used to analyze SF constituents. Centroid and integrated mass chromatographic data were processed by MarkerLynx software to generate a multivariate data matrix. PCA and OPLS-DA were conducted on Pareto-scaled data to analyze the chemical constituents of SF. (A) Separation of SF aqueous extract group and vehicle group in a PCA score plot. The t[1] and t[2] values represent the scores of each sample in principal component 1 and 2, respectively. (B) Loading S-plot generated by OPLS-DA. The Y-axis represents the correlation of each ion to the model, and the X-axis represents the relative abundance of ions. The ions from SF aqueous extract are presented in right-upper window, and several top ranking ions were identified as (I) oxymatrine; (II) oxysophocarpine; (III) matrine; (IV) sophocarpine; and (V) N-methylcytisine.
Figure 3. **Structural elucidation of N-methylcytisine in SF extract.** The analysis of N-methylcytisine and SF extract was performed under the same conditions using UPLC-TOFMS. (A) A chromatogram of authentic N-methylcytisine, retention time at 0.97 min. (B) A chromatogram of N-methylcytisine detected in SF extract, retention time at 0.97 min. (C) MS/MS fragmentation of N-methylcytisine. MS/MS fragmentation was conducted with collision energy ramping from 10 to 30 eV. Major daughter ions from fragmentation were interpreted in the inlaid structural diagram.

Figure 4. **Identification of PXR-activator(s) in SF aqueous extract.** DPX2 cells were incubated for 24 h with individual chemicals identified from SF aqueous extract. Results are shown as the fold induction of luciferase activity over the vehicle control. (A) The effect of individual chemical (10 µM) on PXR activation. These chemicals were identified in SF aqueous extract. Rifampicin served as a positive control for PXR activation. The data are presented as mean ± SD (n=3), *p<0.05 vs control. (B) Concentration-dependent PXR activation in DPX2 cells by N-methylcytisine. The data are presented as mean (n=3 at each concentration).

Figure 5. **Induction of CYP3A4 by SF aqueous extract and N-methylcytisine.** DPX2 cells and HepaRG cells were incubated with SF aqueous extract and N-methylcytisine (10 µM) for 48 h. CYP3A4 mRNA expression was analyzed by qPCR. Values were quantified using the comparative CT method, and samples were normalized to GAPDH. Rifampicin (10 µM) served as a positive control of CYP3A4 inducer. (A) The effect of SF aqueous extract and N-methylcytisine on CYP3A4 expression in DPX2 cells. The data are shown as the fold induction vs control (n=3, *p<0.05 vs control). (B) The effect of SF aqueous extract and N-methylcytisine
on CYP3A4 expression in HepaRG cells. The data are shown as the fold induction vs control (n=3, *p<0.05 vs control). (C) The effect of PXR antagonist sulforaphane (20 µM) on N-methylcytisine–mediated CYP3A4 induction in HepaRG cells. CYP3A4 expression in the N-methylcytisine-treated group was set as 100% (n=3, *p<0.05 vs N-methylcytisine-treated group).

Figure 6. The effect of the pretreatment of SF aqueous extract and its constituents on CYP3A activity in DPX2 cells. DPX2 cells were exposed to SF aqueous extract and its constituents (10 µM each) for 48 h. After the treatment, the culture medium containing SF aqueous extract or its constituents was withdrawn and changed to the medium containing 50 µM midazolam. Midazolam was used as a probe for CYP3A activity analysis. 1'-hydroxy-midazolam was analyzed by UPLC-TOFMS. CYP3A activity in the control group was set as 1. Rifampicin (10 µM) served as a positive control. All data are presented as mean ± SD (n=3, *p<0.05 vs control).
Figure 5

A

- N-Methylcytisine
- Rifampicin
- SF 5 g/L
- SF 1 g/L
- SF 0.5 g/L
- Control

CYP3A4 mRNA in DPX2 (fold vs control)

B

- N-Methylcytisine
- Rifampicin
- SF 0.5 g/L
- Control

CYP3A4 mRNA in HepaRG (fold vs control)

C

- N-Methylcytisine + Sulforaphane
- N-Methylcytisine

CYP3A4 mRNA in HepaRG (% vs N-Methylcytisine)
Figure 6

- Oxymatrine
- N-methylcyclohexanamine
- Sophocarpine
- Sophoranol
- Allomatrione
- SF 1 g/L
- Rifampicin
- Control

CYP3A activity (fold vs control)